Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,480 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
15.7
Industry P/E
--
EV/EBITDA
-0.1
Div. Yield
0 %
Debt to Equity
0.4
Book Value
$3
EPS
$-4.3
Face value
--
Shares outstanding
61,048,428
CFO
$-728.22 Mln
EBITDA
$-1,106.09 Mln
Net Profit
$-1,127.64 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| 45.3 | 51.6 | 45.3 | 1,487.1 | 87.1 | -17.9 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
| 181.0 | 224.2 | -57.5 | -91.6 | -42.3 | 104.2 | 913.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kodiak Sciences (KOD)
|
40.6 | 2,480.4 | 0.0 | -230.0 | -- | -149.5 | -- | 15.7 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 64.5 | 7,640.4 | 1,396.6 | 316.9 | 59.8 | 153.6 | 25.2 | 156.5 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular... endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Read more
Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
Co-Founder, Chairman, CEO & President
Dr. Victor Perlroth M.D.
Headquarters
Palo Alto, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kodiak Sciences Inc (KOD) is $40.63 (NASDAQ) as of 02-Apr-2026 18:08 EDT. Kodiak Sciences Inc (KOD) has given a return of 87.13% in the last 3 years.
Since, TTM earnings of Kodiak Sciences Inc (KOD) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.44
|
9.42
|
|
2024
|
-2.99
|
3.51
|
|
2023
|
-0.61
|
0.59
|
|
2022
|
-1.12
|
0.85
|
|
2021
|
-16.51
|
6.65
|
The 52-week high and low of Kodiak Sciences Inc (KOD) are Rs 45.60 and Rs 1.92 as of 05-Apr-2026.
Kodiak Sciences Inc (KOD) has a market capitalisation of $ 2,480 Mln as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kodiak Sciences Inc (KOD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-2.18
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.